Genetic Immunity and ViroStatics, both spin-offs of the non-profit Research Institute for Genetic and Human Therapy (RIGHT), are developing novel immunotherapies for HIV/AIDS and other chronic diseases.

The two companies are in the process of combining to form Immunacia - a multinational biopharmaceutical company with Business, Medical and Legal operations in the USA and Research facilities in Hungary and Italy.

Individually, the Companies have pioneered the areas of synthetic plasmid DNA-containing nanomedicine vaccines and oral AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) for chronic diseases including HIV/AIDS and cancer. Together as Immunacia, they are dedicated to accelerating the development of these and additional novel immunotherapies that partner with the immune system to improve human health.

To learn more about the two companies coming together to form Immunacia, their technology platforms, and opportunities for partnering, click on each Company's logo to view their individual web sites.